WEDNESDAY, April 9, 2025 (HealthDay News) -- An experimental drug can help patients with advanced multiple sclerosis (MS) ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

Using eye-tracking -- a technique for recording and analyzing eye movements -- a team has shown that individuals with multiple disabilities can improve their social and emotional skills. Although ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 ...

Using eye-tracking—a technique for recording and analyzing eye movements—a team from the University of Geneva (UNIGE) has ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...